Reviva Pharmaceuticals Holdings, Inc. announced that 446 participants have completed their long-term open-label extension (OLE) trial for brilaroxazine, with 156 participants receiving one year of ...
Abviax's Obefazimod shows promising phase 2b results in ulcerative colitis, with superior safety and efficacy compared to existing treatments, supporting a buy rating. The drug's novel mechanism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results